Using polynomial regression methods, we developed coefficients to accurately measure GFR from a single-compartment model. These coefficients were employed to recalculate the GFR and compare these to values measured with the two-compartment four-sample model in 361 of these children in their second clinic visit. There was excellent correlation (r = 0.999) and no bias or change
in between-individuals’ dispersion. Hence, the GFR can be accurately measured in children with chronic kidney disease using the slow component of the iohexol plasma disappearance curve, provided the duration of study is at least 5 h. Kidney International (2010) 77, 65-71; doi:10.1038/ki.2009.398; published online 21 October 2009″
“BACKGROUND
Aspirin and low-molecular-weight heparin are prescribed for women with unexplained recurrent miscarriage, with the goal of improving the rate of live LXH254 supplier births, but limited data from randomized, controlled trials are available to support the use of these drugs.
METHODS
In this randomized trial, we enrolled 364 women between the G418 in vivo ages of 18 and 42 years who had a history of unexplained recurrent miscarriage and were attempting to conceive or were less than 6 weeks pregnant. We then randomly assigned them to receive daily 80 mg of aspirin plus open-label
subcutaneous nadroparin (at a dose of 2850 IU, starting as soon as a viable pregnancy was demonstrated), 80 mg of aspirin alone, or placebo. The primary outcome measure was the live-birth rate. Secondary outcomes included rates of miscarriage, obstetrical complications, and maternal and fetal adverse events.
RESULTS
Live-birth rates did not differ significantly among the three study groups. The proportions of women who gave birth to a live infant were 54.5% in the group receiving aspirin PDK4 plus nadroparin (combination-therapy group), 50.8% in the aspirin-only group,
and 57.0% in the placebo group (absolute difference in live-birth rate: combination therapy vs. placebo, -2.6 percentage points; 95% confidence interval [CI], -15.0 to 9.9; aspirin only vs. placebo, -6.2 percentage points; 95% CI, -18.8 to 6.4). Among 299 women who became pregnant, the live-birth rates were 69.1% in the combination-therapy group, 61.6% in the aspirin-only group, and 67.0% in the placebo group (absolute difference in live-birth rate: combination therapy vs. placebo, 2.1 percentage points; 95% CI, -10.8 to 15.0; aspirin alone vs. placebo -5.4 percentage points; 95% CI, -18.6 to 7.8). An increased tendency to bruise and swelling or itching at the injection site occurred significantly more frequently in the combination-therapy group than in the other two study groups.
CONCLUSIONS
Neither aspirin combined with nadroparin nor aspirin alone improved the live-birth rate, as compared with placebo, among women with unexplained recurrent miscarriage. (Current Controlled Trials number, ISRCTN58496168.